Sun Pharma balance sheet and annual report FY2025-26

Sun Pharmaceutical Industries Limited reported consolidated revenue from operations of ₹58,462 crore for FY2025-26 (the year to 31 March 2026) and a net profit of ₹11,479 crore for its shareholders, a net margin of 19.6%. Below are five years of figures from its own annual reports, the ratios worked out from them and links to each report.

Figures from the company's published annual reports. Not investment advice. All figures are consolidated, in ₹ crore, for years ending 31 March. A blank cell means the figure was not in the report we used.

Sun Pharma annual reports, checked 18 November 2026

Key figures, FY2021-22 to FY2025-26

Sun Pharma consolidated figures by year
₹ croreFY2021-22FY2022-23FY2023-24FY2024-25FY2025-26
Revenue from operations38,65443,88648,49752,57858,462
Total income39,57644,52049,85154,54360,434
Net profit attributable to owners3,2738,4749,57610,92911,479
EPS, basic (₹)13.6035.3039.9045.6047.80
Total assets69,80880,74485,46392,1011,08,785
Equity attributable to owners48,01155,99563,66772,21883,570
Total borrowings9316,1982,8451,8704,081
Cash from operations8,9854,95912,13514,07212,419
Capital expenditure1,4952,0862,2022,1293,609

Total borrowings are non-current plus current borrowings, without lease liabilities. Capital expenditure is the line “Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development)” in the cash flow statement.

Revenue from operations and net profit, ₹ crore, consolidated
FY2021-22 Revenue from operations: ₹38,654 croreFY2021-22 Net profit: ₹3,273 crore2021-22FY2022-23 Revenue from operations: ₹43,886 croreFY2022-23 Net profit: ₹8,474 crore2022-23FY2023-24 Revenue from operations: ₹48,497 croreFY2023-24 Net profit: ₹9,576 crore2023-24FY2024-25 Revenue from operations: ₹52,578 croreFY2024-25 Net profit: ₹10,929 crore2024-25FY2025-26 Revenue from operations: ₹58,462 croreFY2025-26 Net profit: ₹11,479 crore2025-26

Revenue from operations Net profit attributable to owners

What changed in FY2025-26

Ratios worked out from these figures

RatioFY2021-22FY2022-23FY2023-24FY2024-25FY2025-26
Net margin8.5%19.3%19.7%20.8%19.6%
Return on equity16.3%16.0%16.1%14.7%
Debt to equity0.020.110.040.030.05
Asset growth15.7%5.8%7.8%18.1%

Return on equity and asset growth need the year before, so the first column is blank. How to read a balance sheet explains each line.

Reading these figures

Where to read the full report

Reports are on Sun Pharma's own website, sunpharma.com. We summarise figures only; the reports themselves carry the full statements, notes and the auditor's opinion.

Questions

What is Sun Pharma's net profit for FY2025-26?

Sun Pharma's consolidated net profit attributable to its shareholders was ₹11,479 crore in FY2025-26, up 5.0% from ₹10,929 crore in FY2024-25, as shown in its Annual Report 2025-26: consolidated financial statements.

What is Sun Pharma's revenue for FY2025-26?

Consolidated revenue from operations was ₹58,462 crore in FY2025-26.

How much has Sun Pharma borrowed?

Total borrowings were ₹4,081 crore at 31 March 2026, against equity attributable to owners of ₹83,570 crore.

Where can I download Sun Pharma's annual report?

The Annual Report 2025-26: consolidated financial statements is a PDF on the company's website. The links above go straight to the report for each year we used.

More company financials

All companies · How to read a balance sheet · Business and accounting calculators · Balance sheet in the glossary